Drug Type Small molecule drug |
Synonyms- |
Target |
Action- |
Mechanism MDM2-p53 interaction inhibitor(p53-binding protein Mdm-2 p53 interaction inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22O6 |
InChIKeyZPXRQFLATDNYSS-BJMVGYQFSA-N |
CAS Registry31858-66-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Stomach Cancer | Preclinical | United States | 08 Jun 2025 | |
| Stomach Cancer | Preclinical | China | 08 Jun 2025 |





